The night of randomized clinical trials where all patients are black: a need to estimate variability in treatment effects


Published: 22 March 2022
Abstract Views: 1481
PDF: 109
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

Authors

  • Giovanni de Gaetano Department of Epidemiology and Prevention, IRCCS Neuromed, Pozzilli, Italy.
  • Chiara Cerletti Department of Epidemiology and Prevention, IRCCS Neuromed, Pozzilli, Italy.
  • Licia Iacoviello Department of Epidemiology and Prevention, IRCCS Neuromed, Pozzilli, Italy; EPIMED Research Center, Department of Medicine and Surgery, University of Insubria, Varese, Italy.
  • Maria Benedetta Donati Department of Epidemiology and Prevention, IRCCS Neuromed, Pozzilli, Italy.

In the Sixties, the few anti-thrombotic drugs available were administered following several criteria including tradition of the “School”, preference of the doctor in charge, pressure of pharmaceutical companies [...]


Peto R. Aspirin after myocardial infarction. Lancet 1980;1:1172-3. DOI: https://doi.org/10.1016/S0140-6736(80)91626-8

Antithrombotic Trialists' Collaboration. Collaborative metaanalysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 2002;324:71-86. Erratum in: BMJ 2002;324:141. DOI: https://doi.org/10.1136/bmj.324.7329.71

Sackett DL, Rosenberg WM, Gray JA, et al. Evidence based medicine: what it is and what it isn't. BMJ 1996;312:71-2. DOI: https://doi.org/10.1136/bmj.312.7023.71

Liberati A. Need to realign patient-oriented and commercial and academic research. Lancet 2011; 378: 1777-8. DOI: https://doi.org/10.1016/S0140-6736(11)61772-8

de Gaetano G, Cerletti C, Dejana E, Vermylen J. Current issues in thrombosis prevention with antiplatelet drugs. Drugs 1986;31:517-49. DOI: https://doi.org/10.2165/00003495-198631060-00004

Roses AD. Pharmacogenetics and the practice of medicine. Nature 2000;405(6788):857-65. DOI: https://doi.org/10.1038/35015728

Liuzzo G, Patrono C. Give genotype-guided dual antiplatelet therapy a second CHANCE. Eur Heart J 2022;43:938-9. DOI: https://doi.org/10.1093/eurheartj/ehac024

Angus DC, Chang CH. Heterogeneity of treatment effect: estimating how the effects of Interventions vary across individuals. JAMA 2021;326:2312-3. DOI: https://doi.org/10.1001/jama.2021.20552

Athey S, Imbens G. Recursive partitioning for heterogeneous causal effects. Proc Natl Acad Sci U S A 2016;113: 7353-60. DOI: https://doi.org/10.1073/pnas.1510489113

Di Castelnuovo A, Gialluisi A, Antinori A, et al. Disentangling the association of hydroxychloroquine treatment with mortality in Covid-19 hospitalized patients through Hierarchical Clustering. J Healthc Eng 2021;2021:5556207. DOI: https://doi.org/10.1155/2021/5556207

de Gaetano, G. ., Cerletti, C. ., Iacoviello, L. ., & Donati, M. B. . (2022). The night of randomized clinical trials where all patients are black: a need to estimate variability in treatment effects. Bleeding, Thrombosis, and Vascular Biology, 1(1). https://doi.org/10.4081/btvb.2022.24

Downloads

Download data is not yet available.

Citations